MiNEN, amphicrine carcinomas, and conventional carcinomas with neuroendocrine differentiation: diagnostic criteria, open questions, and future perspectives
- PMID: 40931236
- DOI: 10.1007/s00428-025-04241-z
MiNEN, amphicrine carcinomas, and conventional carcinomas with neuroendocrine differentiation: diagnostic criteria, open questions, and future perspectives
Abstract
Mixed neuroendocrine and non-neuroendocrine neoplasms (MiNEN) represent a heterogeneous group of bidirectionally differentiated epithelial malignancies that are, in most cases, highly aggressive. They are defined by the presence of morphologically distinct, yet clonally related, neuroendocrine and non-neuroendocrine components, each comprising at least 30% of the tumor mass according to current guidelines. Tumors that fall within the differential diagnostic spectrum of MiNEN include amphicrine carcinomas-characterized by the co-expression of neuroendocrine and non-neuroendocrine features within the same tumor cell-as well as conventional carcinomas that lack neuroendocrine morphology but exhibit immunohistochemical expression of neuroendocrine markers. However, these entities do not fulfill the current diagnostic criteria for MiNEN. In this review, we aim to outline the current diagnostic framework for MiNEN and examine the conceptual and classification boundaries of amphicrine carcinomas and conventional carcinomas with aberrant neuroendocrine marker expression in relation to what is presently defined as a MiNEN. In addition, we highlight key unresolved questions that should be addressed in future guidelines to streamline the diagnostic process and improve consistency. Finally, we provide an outlook on emerging technologies and future perspectives that may further refine the classification and clinical management of these complex neoplasms.
Keywords: Amphicrine carcinoma; MANEC; MiNEN; Neuroendocrine carcinoma; Neuroendocrine neoplasm; Neuroendocrine tumor.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethical approval: This review was created in compliance with ethical standards, including the declaration of Helsinki. Conflict of interest: The authors declare no competing interests.
References
-
- Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y, Beras A, Spencer R, Lopardo J, Bodd F, Montecalvo J, Sauter JL, Chang JC, Buonocore DJ, Travis WD, Sen T, Poirier JT, Rudin CM, Rekhtman N (2020) SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol 15:1823–1835. https://doi.org/10.1016/j.jtho.2020.09.009 - DOI - PubMed - PMC
-
- Bellizzi AM (2020) Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you? Hum Pathol 96:8–33. https://doi.org/10.1016/j.humpath.2019.12.002 - DOI - PubMed
-
- Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) WHO classification of tumours of the digestive system. World Health Organization
-
- Chen J, Larsson L, Swarbrick A, Lundeberg J (2024) Spatial landscapes of cancers: insights and opportunities. Nat Rev Clin Oncol 21:660–674. https://doi.org/10.1038/s41571-024-00926-7 - DOI - PubMed
-
- Chen RJ, Ding T, Lu MY, Williamson DFK, Jaume G, Song AH, Chen B, Zhang A, Shao D, Shaban M, Williams M, Oldenburg L, Weishaupt LL, Wang JJ, Vaidya A, Le LP, Gerber G, Sahai S, Williams W, Mahmood F (2024) Towards a general-purpose foundation model for computational pathology. Nat Med 30:850–862. https://doi.org/10.1038/s41591-024-02857-3 - DOI - PubMed - PMC
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
